View Older Stories View More Recent Stories

Jul 1, 2019 10:00AM Pfizer Completes Acquisition of Therachon
Jul 1, 2019 08:04AM Pfizer (PFE) Reports Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment
Jul 1, 2019 08:00AM Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis
Jun 28, 2019 04:06PM Pfizer (PFE) Phase 3 Trial of Revatio in Newborns with PPHN Did Not Meet its Primary Efficacy Endpoint
Jun 28, 2019 04:05PM Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension
Jun 28, 2019 10:16AM Pfizer (PFE) Presents Initial Clinical Data on Phase 1b Gene Therapy Study for DMD
Jun 28, 2019 10:15AM Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)
Jun 28, 2019 07:35AM Pfizer (PFE) Announces FDA Approval for Its Oncology Biosimilar, ZIRABEV
Jun 28, 2019 07:33AM Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)
Jun 27, 2019 04:20PM Pfizer (PFE) Reports Election of Dr. Scott Gottlieb to Board
Jun 27, 2019 04:17PM Scott Gottlieb Elected to Pfizer’s Board of Directors
Jun 27, 2019 04:15PM Pfizer Declares Third-Quarter 2019 Dividend
Jun 21, 2019 10:47AM Pfizer (PFE) Announce EC Approves TALZENNA for Patients with Inherited BRCA-Mutated Locally Advanced
Jun 21, 2019 10:45AM European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
Jun 17, 2019 06:54AM Pfizer to Acquire Array BioPharma
Jun 17, 2019 06:45AM Pfizer (PFE) to Acquire Array BioPharma (ARRY) in $11.4 Billion Deal, $48/Share
Jun 17, 2019 06:45AM Pfizer to Acquire Array BioPharma
Jun 12, 2019 08:02AM Pfizer (PFE) Announces Results from XELJANZ XR ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with JAK Inhibitor
Jun 12, 2019 08:00AM Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor
Jun 5, 2019 01:30PM Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development
Jun 3, 2019 08:05AM Matinas BioPharma to Present at the 9th Annual LD Micro Invitational
Jun 3, 2019 08:05AM Matinas BioPharma to Present at the 9th Annual LD Micro Invitational
May 24, 2019 04:01PM Pfizer (PFE) Phase 3 Trial of LYRICA in PGTC Seizures Did Not Meet its Primary Endpoint
May 24, 2019 04:00PM Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures
May 21, 2019 08:00AM Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
May 15, 2019 05:01PM Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting
May 15, 2019 07:00AM Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates
May 15, 2019 07:00AM Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates
May 15, 2019 06:46AM Pfizer (PFE) Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib in Patients Aged 12 and Older with Moderate to Severe AD
May 15, 2019 06:45AM Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis
May 14, 2019 07:44PM FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
May 8, 2019 06:46AM Pfizer (PFE) Acquires Therachon for $340M Upfront, $470M Contingent
May 8, 2019 06:45AM Pfizer Acquires Clinical-Stage Biotech Therachon
May 7, 2019 07:10AM Pfizer (PFE) Announces EC Approves LORVIQUA for Certain Adult Patients with Previously-Treated ALK-Positive Advanced NSCLC
May 7, 2019 07:00AM European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
May 6, 2019 06:47AM Pfizer (PFE) Announces U.S. FDA Approves VYNDAQEL and VYNDAMAX for Use in Patients with Transthyretin Amyloid Cardiomyopathy
May 6, 2019 06:45AM U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Apr 26, 2019 11:03AM Pfizer (PFE) Receives Positive CHMP Opinion for TALZENNA
Apr 26, 2019 11:00AM Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
Apr 25, 2019 11:17AM Pfizer Hosts Annual Meeting of Shareholders
Apr 18, 2019 05:06PM Pfizer (PFE). Eli Lilly & Co. (NYSE:LLY) Report Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
Apr 18, 2019 05:05PM Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
Apr 18, 2019 02:00PM Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders
Apr 13, 2019 04:00AM Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults A
Apr 4, 2019 02:58PM Pfizer (PFE) Announces FDA Approval of IBRANCE for Treatment of Men with HR+, HER2- Metastatic Breast Cancer
Apr 4, 2019 02:57PM U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
Apr 3, 2019 09:44AM Pfizer (PFE) Announces VIZIMPRO Receives MAA in EU for First-Line Treatment of Adult Patients with EGFR-Mutated NSCLC
Apr 3, 2019 09:42AM VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Apr 2, 2019 07:01AM Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
Apr 2, 2019 07:00AM Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
View More Recent Stories View Older Stories